WooGene B&G Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
March 20, 2024 at 11:43 am IST
Share
WooGene B&G Co., Ltd reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 0.00001 million. Net loss was KRW 1,183.86 million compared to net income of KRW 849.57 million a year ago.
Basic loss per share from continuing operations was KRW 41 compared to basic earnings per share from continuing operations of KRW 29 a year ago. Basic loss per share was KRW 41 compared to basic earnings per share of KRW 29 a year ago.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
WOOGENE B&G CO., LTD 
